Navigation Links
Catalent to Present Assessment Methods and Design Approaches for T-Cell Manufacturing Challenges at ISCT 2020 Virtual
Date:5/21/2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Jean-François Chaubard, Senior Director, Open Innovation at Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual conference, which takes place on 28 – 29 May, 2020.

On Thursday, 28 May, at 11 a.m. CEST, Mr. Chaubard will present “Allogeneic T-Cell Therapies: Shifting Towards Commercial Manufacturing,” which will discuss the approach that Catalent is adopting to scale-up and commercialize allogeneic cell therapies using its Manufacturing by Design (MbD) methodology. Developed in-house, this methodology is designed to solve the process efficiency and supply chain complexities and challenges associated with T-Cell manufacturing. He will also discuss the importance of establishing a specific and optimized fill and finish platform, and will speak to the combined cell and gene therapy capabilities at Catalent which position the company as a full-service global provider of advanced therapeutics.

Mr. Chaubard has 25 years’ experience in the biotechnology industry and has worked for a number of companies including GSK and Sanofi as well as Contract Manufacturing Organizations including CMC Biologics and Yposkesi. He joined Catalent in 2020 with the company’s acquisition of MaSTherCell, and has been involved in the development and scale-up of different industrial processes based on mammalian cell lines to produce recombinant proteins, vaccines, and viral vectors. His work has focused on the development and implementation of new technologies in the manufacture of advanced therapies.

For more information, please visit https://www.catalent.com/events/isct-2020/.

About Catalent Cell & Gene Therapy
Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, and with deep experience in viral vector scale-up and production. When Catalent recently acquired MaSTherCell, it added expertise in autologous and allogeneic cell therapy development and manufacturing to position Catalent as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has produced more than 100 cGMP batches across 70+ clinical and commercial programs.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_present_assessment_methods_and_design_approaches_for_t_cell_manufacturing_challenges_at_isct_2020_virtual/prweb17136348.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent Receives P&G External Business Partner of the Year Award
2. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
3. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
4. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
5. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
6. Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
7. Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity
8. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award
9. Underrepresented minority students receive fellowships in digestive disease and nutrition research
10. UCLA life scientists present new insights on climate change and species interactions
11. Efficacy of acupressure to relieve migraine nausea presented at International Headache Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2020)... WESTBURY, N.Y. (PRWEB) , ... April 28, 2020 ... ... clients, these webinars are Lachman Consultants latest effort in providing timely and critical ... environment, further complicated by social distancing and health safety concerns. , “Providing the ...
(Date:4/23/2020)... , ... April 23, 2020 , ... ... and recruitment plans. MDG provides critical infrastructure products for the animal feed, human ... previous plans for expansion. Further, as supply channels from overseas competitors have become ...
(Date:4/18/2020)... (PRWEB) , ... April 16, 2020 , ... SIRION ... and cell therapy, today announced it will present a company update on its work ... Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the Company’s ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... May 13, 2020 , ... In collaboration with Sartorius, ... in the Life Science Lab . The comprehensive information source was created for ... and liquid handling to contamination control. , The content hub features the latest ...
(Date:5/5/2020)... ... May 05, 2020 , ... ProductLife Group has marked ... Duburcq joins the group after 13 years at Altran, where he was Group VP ... in Immunology and being a Pharmacist, Xavier was involved in his early career in ...
(Date:4/23/2020)... ... April 22, 2020 , ... Across the ... protect themselves from COVID-19. Virginia has only been receiving 50% to 7.7% of ... (FEMA). , As Governor Northam told the Virginia Mercury, “While we appreciate what ...
(Date:4/18/2020)... ... , ... NeuroFlow has been awarded $750,000 from ... the expansion of its digital health platform enabling behavioral health integration in all ... process, adds to NeuroFlow’s recent government awards . , The SBIR Phase ...
Breaking Biology Technology: